Arvinas, Inc. - Common Stock (ARVN)

Arvinas (NASDAQ:ARVN) said its first quarter was marked by the FDA approval of VEPPANU, a new licensing agreement with Rigel Pharmaceuticals and continued progress across a clinical-stage pipeline focused on targeted protein degradation. President and Chief Executive Officer Randy Teel said the app

Arvinas (ARVN) Q4 2025 Earnings Call Transcript

Randy Teel has been appointed as President, CEO, as well as a member of the Company’s Board of Directors, effective immediately.

Here are the top movers in Tuesday's session, showcasing the stocks with significant price changes.

Today's session on Tuesday is marked by notable gaps in various stocks. Stay informed with the gap up and gap down stocks in today's session.

As the US market prepares to open on Tuesday, let's get an early glimpse into the pre-market session and identify the stocks leading the pack in terms of gains and losses.

Arvinas (ARVN) beat Q3 2025 earnings estimates, with revenue of $41.9M and a smaller-than-expected loss. The biotech also reported strong pipeline progress and a cash runway into 2028.

Arvinas Q2 2025 earnings: Revenue missed estimates at $22.4M, but EPS beat at -$0.84. NDA submitted for vepdegestrant, ARV-102 advances in trials. Shares fell pre-market.

Arvinas and Pfizer submit NDA to FDA for vepdegestrant after Phase 3 data shows efficacy in ESR1-mutated ER+/HER2- breast cancer patients